High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer
High levels of glioma tumor suppressor candidate region gene 1 predicts a poor prognosis for prostate cancer
复制标题
高水平的神经胶质瘤肿瘤抑制候选区域基因 1 预示着前列腺癌的不良预后。
DOI：
10.3892/ol.2018.9490
复制
发表时间：
2018-11-01
期刊：
影响因子：
2.9
通讯作者：
Huang, Hai
中科院分区：
文献类型：
--
作者：
Ma, Xiaoming;Du, Tao;Huang, Hai
胶质瘤肿瘤抑制候选区域基因 1 (GLTSCR1) 与少突胶质细胞瘤的进展相关。然而，GLTSCR1在前列腺癌中的研究却很少。在本研究中，评估了 GLTSCR1 的表达与前列腺癌患者肿瘤进展和预后之间的关联。使用人体组织微阵列对 GLTSCR1 蛋白表达水平进行免疫组织化学分析，并根据前列腺癌患者的临床变量评估免疫染色结果。随后，利用癌症基因组图谱（TCGA）在mRNA水平验证分析结果，并研究GLTSCR1在前列腺癌中的预后价值。免疫组化和TCGA数据分析显示，前列腺癌组织中GLTSCR1的表达显着高于良性前列腺组织（免疫反应评分，P=0.015；mRNA水平：癌，447.7±6.45 vs良性，343.5±4.21；P<0.001）。此外，GLTSCR1蛋白表达增加与前列腺癌组织中的某些临床变量相关，包括临床分期晚期（P<0.001）、肿瘤侵袭增强（P=0.003）、淋巴结转移（P=0.003）和远处转移（P=0.001）。 TCGA数据也显示出相似的结果，表明GLTSCR1 mRNA表达上调与Gleason评分（P<0.001）、肿瘤侵袭增强（P=0.011）、淋巴结转移（P=0.001）和远处转移（P=0.002）相关。此外，Kaplan-Meier 分析表明，在所有患者中，与低 GLTSCR1 表达的患者相比，高 GLTSCR1 表达表明总生存期 (P=0.028) 和无生化复发 (BCR) 生存期 (P=0.004) 降低。最后，多变量分析表明，GLTSCR1 的表达是无 BCR 生存率较差的独立预测因素 (P=0.049)。本研究表明 GLTSCR1 表达增加与前列腺癌的进展相关。此外，GLTSCR1 可能是一种新型生物标志物，能够预测前列腺癌患者的临床结果。
Glioma tumor suppressor candidate region gene 1 (GLTSCR1) is associated with the progression of oligodendroglioma. However, there has been little study of GLTSCR1 in prostate cancer. In the present study, the association between the expression of GLTSCR1, and the progression and prognosis of tumors in patients with prostate cancer was assessed. An immunohistochemical analysis was performed using a human tissue microarray for GLTSCR1 at the protein expression level and the immunostaining results were evaluated against clinical variables of patients with prostate cancer. Subsequently, The Cancer Genome Atlas (TCGA) was used to validate the analysis results at the mRNA level and to study the prognostic value of GLTSCR1 in prostate cancer. Immunohistochemistry and TCGA data analysis revealed that GLTSCR1 expression in the prostate cancer tissues was significantly higher than that in the benign prostate tissues (immunoreactivity score, P=0.015; mRNA levels: cancer, 447.7±6.45 vs. benign, 343.5±4.21; P<0.001). Additionally, the increased GLTSCR1 protein expression was associated with certain clinical variables in the prostate cancer tissues, including advanced clinical stage (P<0.001), enhanced tumor invasion (P=0.003), lymph node metastasis (P=0.003) and distant metastasis (P=0.001). TCGA data revealed similar results, demonstrating that the upregulation of GLTSCR1 mRNA expression was associated with the Gleason score (P<0.001), enhanced tumor invasion (P=0.011), lymph node metastasis (P=0.001) and distant metastasis (P=0.002). Furthermore, Kaplan-Meier analysis suggested that among all patients, high GLTSCR1 expression indicated a decreased overall survival (P=0.028) and biochemical recurrence (BCR)-free survival (P=0.004), compared with patients with low GLTSCR1 expression. Finally, multivariate analysis revealed that the expression of GLTSCR1 was an independent predictor of poor BCR-free survival (P=0.049). The present study suggested that the increased expression of GLTSCR1 was associated with the progression of prostate cancer. Furthermore, GLTSCR1 may be a novel biomarker that is able to predict the clinical outcome in prostate cancer patients.